Thozalinone
 | |
 | |
| Clinical data | |
|---|---|
| Other names | Tozalinone, Thozalinon |
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C11H12N2O2 |
| Molar mass | 204.229 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
| |
| |
  (what is this?) (verify) | |
Thozalinone (USAN) (brand name Stimsen; former developmental code name CL-39808) is a psychostimulant that has been used as an antidepressant in Europe.[1][2][3][4][5] It has also been trialed as an anorectic.[6] Thozalinone is described as a "dopaminergic stimulant",[7] and likely acts via inducing the release of dopamine and to a minimal extent norepinephrine; similar to analogue pemoline, it is reportedly devoid of abuse potential unlike other dopaminergic psychostimulants.[2][7][8]
Synthesis
[edit]
Sodium hydride is used as a strong base to abstract the alcohol proton in ethyl mandelate [774-40-3] (1); addition of the oxyanion to dimethylcyanamide [1467-79-4] gives the intermediate (2). Intramolecular cyclization then occurs giving Thozalinone (3).
Notes
[edit]- In treatment of Parkinsonism: W. D. Gray, C. E. Edward, U.S. patent 3,665,075 (1972 to Am. Cyanamid).
- Pharmacological studies:[11]
See also
[edit]References
[edit]- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 435–. ISBN 978-1-4757-2085-3.
- ^ a b Greenblatt EN, Osterberg AC (July 1965). "Some pharmacologic properties of thozalinone, a new excitant". Toxicology and Applied Pharmacology. 7 (4): 566–78. doi:10.1016/0041-008X(65)90042-6. PMID 4378772.
- ^ Dictionary of organic compounds. London: Chapman & Hall. 1996. ISBN 0-412-54090-8. Archived from the original on 2021-05-31. Retrieved 2021-05-31.
- ^ Merck index on CD-ROM: Windows. London: Chapman & Hall EPD. 1998. ISBN 0-412-82910-X.
- ^ Gallant DM, Bishop MP, Scrignar CB, Hornsby L, Moore B, Inturrisi BB (December 1966). "A double-blind study of thozalinone (C1 39,808) in depressed outpatients". Current Therapeutic Research, Clinical and Experimental. 8 (12): 621–2. PMID 4962734.
- ^ Leite AC, Liepen LL, Costa VP (September 1971). "[Clinical trial of Stimsem Thozalinone in the treatment of obese patients]". Revista Brasileira de Medicina (in Portuguese). 28 (9): 475–8. PMID 5139648.
- ^ a b Yen-Koo HC, Balazs T (1980). "Detection of dopaminergic supersensitivity induced by neuroleptic drugs in mice". Drug and Chemical Toxicology. 3 (2): 237–47. doi:10.3109/01480548009108286. PMID 6112126.
- ^ Yen-Koo HC, Davis DA, Balazs T (1985). "Inhibition of dopaminergic agonist-induced gnawing behavior by neuroleptic drugs in mice". Drug and Chemical Toxicology. 8 (6): 495–502. doi:10.3109/01480548509041072. PMID 2868876.
- ^ Howell CF, Quinones NQ, Hardy Jr RA (May 1962). "2-Amino-2-oxazolin-4-ones. I. Synthesis". The Journal of Organic Chemistry. 27 (5): 1679–1685. doi:10.1021/jo01052a047.
- ^ Lindberg UH, Pedersen J (February 1968). "Compounds related to pemoline. 2-amino-5-aryl-4-oxo-2-oxazolines". Acta Pharmaceutica Suecica. 5 (1): 15–22. PMID 4386169.
- ^ Bernstein BM, Latimer CN (1968). "Behavioral facilitation: The interaction of imipramine and desipramine with amphetamine, alpha-pipradrol, methylphenidate, and thozalinone". Psychopharmacologia. 12 (4): 338–345. doi:10.1007/BF00401412. PMID 4385109. S2CID 31096140.